title: Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved.
abstract: BACKGROUND
  Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma.
  
  
  METHODS
  We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment.
  
  
  CONCLUSIONS
  Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. chiakisaita@cick.jp.
authors.forename: Chiaki
authors.initials: C
authors.lastname: Saita
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. rg02045@cick.jp.
authors.forename: Risa
authors.initials: R
authors.lastname: Goto
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. aruga@cick.jp.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Aruga
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. idenami@cick.jp.
authors.forename: Nami
authors.initials: N
authors.lastname: Idera
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. yayoi.honda@cick.jp.
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Honda
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. horiguchi-k@cick.jp.
authors.forename: Kazumi
authors.initials: K
authors.lastname: Horiguchi
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. miyamoto-h3836@cick.jp.
authors.forename: Hiromi
authors.initials: H
authors.lastname: Miyamoto
authors.affiliation: Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. s.horiguchi@cick.jp.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Horiguchi
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. tyamashita@cick.jp.
authors.forename: Toshinari
authors.initials: T
authors.lastname: Yamashita
authors.affiliation: Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. kurochan@dd.iij4u.or.jp.
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Kuroi
mesh_terms: D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002291:Carcinoma, Papillary / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D005260:Female; D015870:Gene Expression; D006801:Humans; D000077289:Letrozole; D020360:Neoadjuvant Therapy / Q000379:methods; D009570:Nitriles / Q000627:therapeutic use*; D017698:Postmenopause; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D000077289:Letrozole; D009570:Nitriles; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; C508053:ERBB2 protein, human
references.citation: J Natl Cancer Inst Monogr. 2001;(30):96-102
references.pmid: 11773300
references.citation: Ann Oncol. 2001 Nov;12(11):1527-32
references.pmid: 11822750
references.citation: Cancer. 2007 Jul 15;110(2):244-54
references.pmid: 17538978
references.citation: Histopathology. 2015 May;66(6):761-70
references.pmid: 24845113
references.citation: Br J Cancer. 2013 Apr 30;108(8):1587-92
references.pmid: 23579222
references.citation: Ann Oncol. 2013 Sep;24(9):2206-23
references.pmid: 23917950
references.citation: J Clin Oncol. 2013 Nov 1;31(31):3997-4013
references.pmid: 24101045
references.citation: J Cancer Res Clin Oncol. 2013 Jan;139(1):77-84
references.pmid: 22932921